![]() 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 22.239000000203 mixture Substances 0.000 claims abstract description 78.238000004519 manufacturing process Methods 0.000 claims abstract description 192.108090000623 proteins and genes Proteins 0.000 claims abstract description 268.102000004169 proteins and genes Human genes 0.000 claims abstract description 268.239000002609 media Substances 0.000 claims abstract description 334.239000006143 cell culture media Substances 0.000 title claims abstract description 140.229960003080 Taurine Drugs 0.000 title claims abstract description 308.XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 653.Status Active legal-status Critical Current Anticipated expiration legal-status Critical Links Assignors: LAWRENCE, SHAWN, CASEY, Meghan E., JOHNSON, AMY S., OSHODI, Shadia Publication of US20200157492A1 publication Critical patent/US20200157492A1/en Application granted granted Critical Publication of US10927342B2 publication Critical patent/US10927342B2/en US case filed in West Virginia Northern District Court litigation Source: District Court Jurisdiction: West Virginia Northern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). reassignment REGENERON PHARMACEUTICALS, INC. Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc Priority to US16/742,670 priority Critical patent/US10927342B2/en Assigned to REGENERON PHARMACEUTICALS, INC. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority claimed from US201562200689P external-priority First worldwide family litigation filed litigation Critical (B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee Regeneron Pharmaceuticals Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) CASEY Shadia OSHODI Shawn Lawrence Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/742,670 Other versions US20200157492A1 Google Patents Taurine supplemented cell culture medium and methods of useĭownload PDF Info Publication number US10927342B2 US10927342B2 US16/742,670 US202016742670A US10927342B2 US 10927342 B2 US10927342 B2 US 10927342B2 US 202016742670 A US202016742670 A US 202016742670A US 10927342 B2 US10927342 B2 US 10927342B2 Authority US United States Prior art keywords cell taurine cells acid culture medium Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US10927342B2 - Taurine supplemented cell culture medium and methods of use ![]() US10927342B2 - Taurine supplemented cell culture medium and methods of use ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |